Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Narcolepsy – Unmet Need – Unmet Need – Narcolepsy with or without cataplexy (US/EU)
Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…
Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Recurrent or Metastatic Non-Nasopharyngeal Squamous Cell Carcinoma of Head and Neck (US/EU)
Recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck is an aggressive malignancy associated with a high recurrence rate. The approval of immune checkpoint…
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
Approximately 20% of nonsquamous NSCLC in Western patients is driven by mutations in EGFR, and as such is treated predominantly with agents targeting those alterations. The market is currently…
Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)
The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies…
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and topical steroids. Although these therapies can alleviate EoE symptoms, their remission…
Axial Spondyloarthritis – Unmet Need – Unmet Need – Nonradiographic Axial Spondyloarthritis (US/EU)
TNF-alpha inhibitors, such as AbbVie’s Humira, Amgen’s Enbrel, Johnson & Johnson Innovative Medicine’s Simponi, and UCB’s Cimzia, are approved for the treatment of nonradiographic axial…
